All In MedTech

Device Trial Radar · NCT03853356

Evidence For Fusion In Spine With Orthoss®

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Jan 18, 2019

Primary completion

Jul 17, 2025

Study completion Dec 2026

Sponsor

Lead sponsor
Geistlich Pharma AGNot on our public-company list
Sponsor type
Industry
First posted
Feb 25, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the performance and safety of the Orthoss® as a bone graft extender in lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1).

Conditions

  • Lumbar Spondylolisthesis Involving L4-L5
  • Lumbar Spondylolisthesis Involving L5-S1
  • Lumbar Spinal Stenosis
  • Lumbar Disc Degeneration

Interventions

  • OrthossDevice

    Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fusion rateTime frame: 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsklinikum Augsburg - Neurochirurgische Klinik und Poliklinik

    Augsburg, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

  • Klinikum Magdeburg gGmbH

    Magdeburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.